Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
about
Intrabody and Parkinson's diseaseMultimodality and nanoparticles in medical imagingAntibody-based imaging of HER-2: moving into the clinic.Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugatesUnexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning.Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapyRecombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabelingPET/CT and breast cancer.Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imagingInorganic nanoparticle-based contrast agents for molecular imagingTranslational molecular imaging for cancer.An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.Recent trends in antibody-based oncologic imagingA comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.Affinity peptide for targeted detection of dysplasia in Barrett's esophagus.Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-lifeAffibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncologyTailoring antibodies for radionuclide delivery.Self-assembly of antibodies by chemical induction[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.Tumor-associated antigens and biomarkers in cancer and immune therapy.The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis.The absence of a clathrin adapter confers unique polarity essential to proximal tubule functionIn vivo Noninvasive Small Animal Molecular ImagingSite-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumorsEvaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumabHuman monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.Antibody vectors for imaging.Immuno-positron emission tomography in cancer models.Pretargeted molecular imaging and radioimmunotherapy.
P2860
Q24653530-4505DEB9-2603-45CD-9970-4934A0CC8AD9Q30407070-53635D17-1FD2-43B4-A25A-BEA96DFC642AQ30423880-6FEBD559-4763-454C-92EE-E746FAC0EB84Q30480648-D5D9D10E-EEAC-4208-8F5D-1C2514608445Q30497599-5F6C2FC9-5EE4-4563-9A9C-09C0A5453B36Q33353929-D00717C0-FC53-4CAE-961D-B4FF61812B3EQ33781006-F8B2137B-F257-40AA-B6DA-7BBFCDCD4A63Q34148890-D01921C4-C366-4B2C-9BB6-BA0F0C98AE1CQ34256370-08E8FD1C-1634-4581-B750-E87DCE6291A0Q34354220-EB4B70B7-8F62-4F00-A9DF-6C4264B1AFA2Q34644628-9DF205C2-A300-44C7-94BC-E1BF46A1F268Q35173093-DFB5C6D4-38C8-4346-A411-6DC52DC900FAQ35583305-AE95A114-DA3B-4B49-86AC-01B229894346Q35636908-FDF75E3F-1A50-4544-BCE7-1AAFF8F7B0D1Q35643425-ADA215D3-8F0F-481C-B583-5DCFFAEC5ED3Q35650526-AB258585-59EF-4A1F-806D-8D60CD7AB4DFQ35870232-3BC90DA3-4A06-4603-8C24-1BCC362E99F6Q36080399-CC6442B5-F452-4418-8C82-A0371409EC36Q36100348-4ACB5262-AAFE-45E6-A227-C1133946F957Q36339722-ACEF68FB-EA77-401A-8BB2-B3939A89E7FBQ36349687-D05E3AB0-5110-4720-BB8E-629CB84FE0FCQ36611798-8A1F1656-A4C9-4D97-88A6-0AF6B19190CCQ36627997-A6D5563F-D2F3-4458-B939-048DE04617C7Q36844959-F19E9EB3-D803-47DC-862D-64994E58A52EQ36903804-5871A623-6E24-4EC5-BB49-2BB22431A84CQ36934328-B8D8F125-6D4C-4859-8829-62FB2C63CF1DQ37083100-A6D2024F-E21A-415F-9D37-11CE1C1527D0Q37158166-4A7FE1FD-70A5-4867-ABCB-3849C28A6726Q37172093-F3D6B7A9-564F-4C13-B77D-23BCC7E2F39AQ37273125-B1CD98FB-5EC1-48A3-9664-0AB0539C49E7Q37289040-00421713-A6C2-459D-842C-15F79E519709Q37289392-C334C184-C3E1-4180-A4CB-29B87EFA7E0EQ37289402-F67B7A3E-F2A0-4C4F-A129-E7B6A1C0BDCFQ37330712-5BBC9676-6E16-4C9E-899B-55E0E92760F0Q37394278-025693CE-30C6-40B4-B50C-9BEA8DE9640AQ37453801-110AF7C1-6646-4FB9-A8EA-C0ECFBC55E8AQ37519517-8F663E0E-BDFA-48C9-AAF8-29858F570042Q37720850-5BDD50AF-F7DD-4AFE-8BD1-4EEE4BE33ED9Q37720853-7A18A504-FB5C-4B26-8ACA-E9FFD7799822Q38022016-F2EAA17D-C332-4EB0-B326-C31A7A8E2BA9
P2860
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@ast
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@en
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@nl
type
label
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@ast
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@en
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@nl
prefLabel
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@ast
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@en
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@nl
P2093
P2860
P1433
P1476
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
@en
P2093
Andrew A Raubitschek
Anne-Line Anderson
Desiree Crow
Gobalakrishnan Sundaresan
Jeffrey Y C Wong
John E Shively
Lawrence E Williams
Michael F Press
P2860
P304
P356
10.1158/0008-5472.CAN-04-4472
P407
P577
2005-07-01T00:00:00Z